|http://ghr.nlm.nih.gov/ A service of the U.S. National Library of Medicine®|
The official name of this gene is “collagen, type VI, alpha 3.”
COL6A3 is the gene's official symbol. The COL6A3 gene is also known by other names, listed below.
The COL6A3 gene provides instructions for making one component of type VI collagen, which is a flexible protein that surrounds muscle cells. Specifically, the protein produced from the COL6A3 gene is the alpha(α)3(VI) chain of type VI collagen. This chain combines with two other types of α(VI) chains (the α1 and α2 chains) to make a molecule called a collagen VI monomer. Two collagen VI monomers attach (bind) together to form collagen VI dimers. Two dimers group together to form a larger molecule called a tetramer, which is the complete type VI collagen molecule.
Type VI collagen molecules form complex networks that make up a large portion of the extracellular matrix surrounding muscle cells. The extracellular matrix is an intricate lattice that forms in the space between cells and provides structural support. The extracellular matrix that surrounds muscle cells is necessary for muscle cell stability and growth. Type VI collagen networks play an especially important role in the extracellular matrix of muscle that is used for movement (skeletal muscle).
At least 10 mutations in the COL6A3 gene have been found to cause Bethlem myopathy. Most of these mutations change single protein building blocks (amino acids) in the α3(VI) chain, which alters its structure. If the abnormal chain is not incorporated into type VI collagen, but is instead broken down soon after it is made, then not enough α3(VI) chain is available for the formation of type VI collagen. The loss of this chain leads to decreased amounts of this type of collagen.
In people with Bethlem myopathy, some normal type VI collagen is produced, but not enough to form a strong extracellular matrix. Over time, a deficient extracellular matrix leads to muscle weakness and the other signs and symptoms of Bethlem myopathy. Mutations in the COL6A3 gene are responsible for approximately 15 percent of all cases of Bethlem myopathy.
At least 10 mutations in the COL6A3 gene have been found to cause Ullrich congenital muscular dystrophy. Some of these mutations change single amino acids and some disrupt the way the gene's instructions are used to make the α3(VI) chain. These mutations result in an absence or severe deficiency of type VI collagen. A lack of type VI collagen disrupts the extracellular matrix surrounding muscle cells, leading to muscle weakness and the other signs and symptoms of Ullrich congenital muscular dystrophy.
Cytogenetic Location: 2q37
Molecular Location on chromosome 2: base pairs 237,324,011 to 237,414,206
The COL6A3 gene is located on the long (q) arm of chromosome 2 at position 37.
More precisely, the COL6A3 gene is located from base pair 237,324,011 to base pair 237,414,206 on chromosome 2.
See How do geneticists indicate the location of a gene? (http://ghr.nlm.nih.gov/handbook/howgeneswork/genelocation) in the Handbook.
You and your healthcare professional may find the following resources about COL6A3 helpful.
You may also be interested in these resources, which are designed for genetics professionals and researchers.
See How are genetic conditions and genes named? (http://ghr.nlm.nih.gov/handbook/mutationsanddisorders/naming) in the Handbook.
acids ; cell ; collagen ; congenital ; deficiency ; extracellular ; extracellular matrix ; gene ; molecule ; muscular dystrophy ; protein ; skeletal muscle
You may find definitions for these and many other terms in the Genetics Home Reference Glossary (http://www.ghr.nlm.nih.gov/glossary).
The resources on this site should not be used as a substitute for professional medical care or advice. Users seeking information about a personal genetic disease, syndrome, or condition should consult with a qualified healthcare professional. See How can I find a genetics professional in my area? (http://ghr.nlm.nih.gov/handbook/consult/findingprofessional) in the Handbook.